Table 2.

Patients’ treatment and outcome according to histology (Per Protocol population n = 27).

		Other malignant CNS tumor
	Ependymoma (n = 8)	High grade glioma (n = 5)	Low grade glioma (n = 10∗)	Other (n = 4)	Total (n = 19)
Tumor status
Refractory tumors		3 (60%)	5 (50%)	1 (25%)	9 (47%)
Relapse	5 (63%)	1 (20%)		1 (25%)	2 (11%)
Refractory relapse	3 (37%)	1 (20%)	5 (50%)	2 (50%)	8 (42%)
Number of cycle of treatment received	1.8 [1.3–2.0]	0.5 [0.5–1.5]	6.8 [2.0–11.0]	1.0 [0.8–1.3]	2.0 [0.5–9.0]
Response after 2 cycles of treatment
Without progression	1 (13%)	1 (20%)	8 (80%)		9 (48%)
Progression	7 (87%)	4 (80%)	2 (20%)	4 (100%)	10 (52%)
“Best response” after any nr of cycle
CR or PR			2 (20%)		2 (10%)
Stable	1 (13%)	1 (20%)	6 (60%)		7 (37%)
Progression	7 (87%)	4 (80%)	2 (20%)	4 (100%)	10 (53%)
Median of PFS (days)	109	48	–	70.0	105

Data are median [range] and n(%) of patients. nr, number; PFS, progression-free survival. Median PFS was not attained for LGG. ^∗Eleven patients with LGG included with one patient not assessable at two cycles.